{"id":"allogenic-human-islet-cells","safety":{"commonSideEffects":[{"rate":null,"effect":"Graft rejection"},{"rate":null,"effect":"Immunosuppression-related infections"},{"rate":null,"effect":"Immunosuppression-related malignancy risk"},{"rate":null,"effect":"Bleeding or thrombosis at transplant site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This cell therapy involves transplanting insulin-secreting islet cells derived from donor pancreatic tissue into patients with type 1 diabetes or other conditions of severe insulin deficiency. The transplanted cells engraft and function to produce and release insulin in response to blood glucose levels, thereby restoring endogenous glucose regulation. The allogeneic (non-self) source requires immunosuppression to prevent rejection.","oneSentence":"Allogeneic human islet cells restore insulin-producing capacity by replacing or supplementing the patient's own dysfunctional beta cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:08:17.912Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus with severe hypoglycemic unawareness"},{"name":"Brittle diabetes with recurrent severe hypoglycemic episodes"}]},"trialDetails":[{"nctId":"NCT03746769","phase":"PHASE1, PHASE2","title":"Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-07-07","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT01630850","phase":"NA","title":"Islet Transplantation in Patients With \"Brittle\" Type I Diabetes","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT01241864","phase":"PHASE2","title":"Islet Transplantation in Type 1 Diabetic Kidney Allograft","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT00160732","phase":"PHASE1, PHASE2","title":"Allogenic Islet Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2003-10","conditions":"Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT01909245","phase":"PHASE2","title":"Islet Cell Transplant for Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2013-10-16","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT04198350","phase":"NA","title":"Pancreatic Islet Transplantation to the Anterior Chamber of the Eye","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2022-09-01","conditions":"Type 1 Diabetes, Visual Impairment","enrollment":""},{"nctId":"NCT01606475","phase":"","title":"Islet Transplant for Type 1 or Surgical Diabetes","status":"NO_LONGER_AVAILABLE","sponsor":"University of Minnesota","startDate":"","conditions":"Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes","enrollment":""},{"nctId":"NCT06751199","phase":"NA","title":"UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-12-30","conditions":"Diabetes","enrollment":16},{"nctId":"NCT03791567","phase":"","title":"Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"APPROVED_FOR_MARKETING","sponsor":"CellTrans Inc.","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT02916680","phase":"NA","title":"Pancreatic Islet Transplantation in the Anterior Chamber of the Human Eye - a Pilot Study","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-03","conditions":"Type 1 Diabetes Mellitus","enrollment":4},{"nctId":"NCT02803905","phase":"PHASE2","title":"Islet Transplant Alone in OMENtum","status":"UNKNOWN","sponsor":"Lorenzo Piemonti","startDate":"2016-04","conditions":"Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1","enrollment":12},{"nctId":"NCT05990530","phase":"PHASE2","title":"Allogeneic Transplantation of Expanded Pancreatic Islet Cells","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-02-22","conditions":"Brittle Type 1 Diabetes","enrollment":6},{"nctId":"NCT00501709","phase":"PHASE1, PHASE2","title":"Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-02","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT01148680","phase":"PHASE3","title":"Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT00434811","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Type 1 Diabetes Mellitus","enrollment":48},{"nctId":"NCT00790257","phase":"PHASE1","title":"Safety and Efficacy Study of Encapsulated Human Islets Allotransplantation to Treat Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2008-11","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00468117","phase":"PHASE3","title":"Efficacy of Islet After Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00260234","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients","status":"TERMINATED","sponsor":"Novocell","startDate":"2005-11","conditions":"Diabetes Mellitus, Type 1","enrollment":12},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Islet transplant, islet transplantation"],"phase":"phase_2","status":"active","brandName":"Allogenic Human Islet Cells","genericName":"Allogenic Human Islet Cells","companyName":"City of Hope Medical Center","companyId":"city-of-hope-medical-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"Allogeneic human islet cells restore insulin-producing capacity by replacing or supplementing the patient's own dysfunctional beta cells. Used for Type 1 diabetes mellitus with severe hypoglycemic unawareness, Brittle diabetes with recurrent severe hypoglycemic episodes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}